DBV Technologies (DBV) Proxy filing summary

Executive summary

• The annual general meeting will address 39 resolutions, including approval of 2024 financial statements, compensation policies, director renewals, and significant capital structure authorizations.

• The company faced regulatory delays in its clinical programs but secured FDA alignment for its Viaskin Peanut patch, completed a major financing, and is now fully funded through potential commercial launch.

• The board recommends voting in favor of all proposals, which include both ordinary and extraordinary matters, such as share buybacks, capital increases, and amendments to bylaws.

Voting matters and shareholder proposals

• Shareholders will vote on approval of annual and consolidated financial statements, allocation of losses, and deficit to share premium.

• Proposals include approval of related-party transactions, director renewals, compensation policies, share buyback authorization, and multiple capital increase delegations.

• Extraordinary resolutions cover capital increases, waivers of preferential rights, equity plans, mergers, and amendments to bylaws.

• Board recommends a vote “FOR” all resolutions.

Board of directors and corporate governance

• Board consists of ten members, majority independent, with gender diversity requirements met.

• Directors are elected for three-year terms, with staggered expiration to ensure continuity.

• Board leadership is separated between an independent chairman and CEO.

• Committees include Audit, Compensation, and Nominating and Governance, all with written charters and compliance with French and Nasdaq standards.

• Board and committees met frequently in 2024, with high attendance.